Safety & regulatory status
BPC-157’s safety story has two very different halves. The preclinical package is genuinely tidy: a multi-species toxico…
A reassuring preclinical package, a near-empty human record, and a hard legal line
BPC-157’s safety story has two very different halves. The preclinical package is genuinely tidy: a multi-species toxicology evaluation reported good tolerance and no clear toxicity signals. The human half is almost blank, with one phase 1 abstract and no long-term data, so "well tolerated in rats" is being asked to carry far more weight than it can.
Layered on top is a clear regulatory picture. BPC-157 is not FDA-approved, was on the FDA interim 503A category 2 compounding list until the FDA removed it in April 2026 (removal is not approval, and it is still not authorized for compounding), and is prohibited for athletes under WADA S0. This unit, current as of mid-2026, separates the reassuring parts from the open questions and the legal facts.